Beall H D, Murphy A M, Siegel D, Hargreaves R H, Butler J, Ross D
School of Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA.
Mol Pharmacol. 1995 Sep;48(3):499-504.
Bioreductive antitumor quinones require reductive metabolism to produce their cytotoxic effects. A series of these compounds was screened for relative rates of reduction by the two-electron reductase, NAD(P)H:quinone oxidoreductase (DTD). The antitumor quinones streptonigrin (SN), 2,5-diaziridinyl-3-phenyl-1,4-benzoquinone (PDZQ), 2,5-diaziridinyl-3,6-dimethyl-1,4-benzoquinine (MeDZQ), and [3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)-propen ol] (EO9) were all excellent substrates for recombinant rat and human DTD. All four compounds were reduced by DTD at least 100 times faster than the clinically important bioreductive alkylating agent, mitomycin C (MC). Reduction of the antitumor quinones was generally 4-5 times more efficient by rat DTD than by human DTD. The exception was EO9, which, surprisingly, was reduced 23 times faster by rat DTD than by human DTD. The rate of reduction of each individual quinone was similar under either aerobic or anaerobic conditions, suggesting that DTD may be an important activating enzyme in the hypoxic fraction of solid tumors. The cytotoxicity of MeDZQ and MC was examined in a panel of human breast and lung cancer cell lines. The data showed good correlations between DTD activity and toxicity for both MeDZQ (r = 0.57, p = 0.054) and MC (r = 0.69, p = 0.020), confirming biochemical data that both compounds are bioactivated by DTD. In addition, IC50 values were in general lower for MeDZQ than for MC in cell lines containing elevated DTD, a finding that was consistent with metabolic data that indicated that MeDZQ was a better substrate for DTD than MC. SR, defined as the ratio of the IC50 value for the H596 NSCLC cell line (undetectable DTD activity) to the IC50 value for the H460 NSCLC cell line (high DTD activity), were determined for all five antitumor quinones. SN was the most selective (SR = 86) followed by EO9 (SR = 62), MeDZQ (SR = 17), and MC (SR = 11). Surprisingly, PDZQ, an excellent substrate for DTD, was toxic to both cell lines (SR = 1.8). These data suggest that antitumor quionones that are substrates for DTD may be selectively toxic to tumors with high DTD activity and may be useful in the treatment of those tumors.
生物还原抗肿瘤醌类化合物需要通过还原代谢来产生细胞毒性作用。对一系列此类化合物进行了筛选,以检测它们被双电子还原酶NAD(P)H:醌氧化还原酶(DTD)还原的相对速率。抗肿瘤醌类化合物链黑菌素(SN)、2,5-二氮丙啶基-3-苯基-1,4-苯醌(PDZQ)、2,5-二氮丙啶基-3,6-二甲基-1,4-苯醌(MeDZQ)和[3-羟甲基-5-氮丙啶基-1-甲基-2-(1H-吲哚-4,7-二酮)-丙烯醇](EO9)都是重组大鼠和人DTD的优良底物。所有这四种化合物被DTD还原的速度比临床上重要的生物还原烷基化剂丝裂霉素C(MC)至少快100倍。大鼠DTD对抗肿瘤醌类化合物的还原效率通常比人DTD高4至5倍。例外的是EO9,令人惊讶的是,大鼠DTD对其的还原速度比人DTD快23倍。在有氧或无氧条件下,每种醌类化合物的还原速率相似,这表明DTD可能是实体瘤缺氧部分的一种重要激活酶。在一组人乳腺癌和肺癌细胞系中检测了MeDZQ和MC的细胞毒性。数据显示,对于MeDZQ(r = 0.57,p = 0.054)和MC(r = 0.69,p = 0.020),DTD活性与毒性之间均具有良好的相关性,证实了这两种化合物均被DTD生物激活的生化数据。此外,在DTD水平升高的细胞系中,MeDZQ的IC50值总体上低于MC,这一发现与代谢数据一致,即表明MeDZQ作为DTD的底物比MC更好。测定了所有五种抗肿瘤醌类化合物的SR,SR定义为H596非小细胞肺癌细胞系(无法检测到DTD活性)的IC50值与H460非小细胞肺癌细胞系(高DTD活性)的IC50值之比。SN的选择性最高(SR = 86),其次是EO9(SR = 62)、MeDZQ(SR = 17)和MC(SR = 11)。令人惊讶的是,作为DTD优良底物的PDZQ对两种细胞系均有毒性(SR = 1.8)。这些数据表明,作为DTD底物的抗肿瘤醌类化合物可能对具有高DTD活性的肿瘤具有选择性毒性,并且可能在这些肿瘤的治疗中有用。